Journal Watch · Nature Biomedical Engineering · 2026

A targeted vector for brain endothelial cell gene delivery and cerebrovascular malformation modelling.

Thus, our rAAV-miniBEND system provides a widely applicable tool for cerebrovascular disease modelling and local or global brainEC gene delivery.

Li JL, Bi Z, Chen XJ et al.Nature Biomedical Engineering3 min readPharma relevance 40/100

DOI: 10.1038/s41551-025-01538-xPMID: 41162685Study type: preclinical (animal / model) study

TL;DR

Thus, our rAAV-miniBEND system provides a widely applicable tool for cerebrovascular disease modelling and local or global brainEC gene delivery.

Key findings

  • Furthermore, we used rAAV-miniBEND to model sporadic cerebral cavernous malformations mediated by MAP3K3<sup>I441M</sup> and AVMs mediated by Braf<sup>V600E</sup>.
  • Somatic expression of Braf<sup>V600E</sup> in brainECs induced an AVM phenotype, revealing that brainEC proliferation is important for AVM development.
  • Thus, our rAAV-miniBEND system provides a widely applicable tool for cerebrovascular disease modelling and local or global brainEC gene delivery.

What they did

Here we develop a recombinant adeno-associated virus (rAAV) tool termed miniBEND (rAAV-based mini-system for brain endothelial cells, rAAV-miniBEND), which combines a minimal promoter and an optimized cis-acting element isolated from the mouse gene Tek. This system activates gene expression specifically in mouse and rat brainECs. rAAV-miniBEND achieved high-efficiency and high-specificity gene expression in brainECs through intracranial injection at various developmental stages and through intravenous administration at all postnatal stages in mice.

Full abstract (original)

Background: Defects in brain endothelial cells (brainECs) can cause severe cerebrovascular malformations, including arteriovenous malformation (AVM) and cerebral cavernous malformation. The lack of appropriate tools for cerebrovascular disease modelling and local genetic manipulation of the brain vasculature hinders research on cerebrovascular malformations.

What they did: Here we develop a recombinant adeno-associated virus (rAAV) tool termed miniBEND (rAAV-based mini-system for brain endothelial cells, rAAV-miniBEND), which combines a minimal promoter and an optimized cis-acting element isolated from the mouse gene Tek. This system activates gene expression specifically in mouse and rat brainECs. rAAV-miniBEND achieved high-efficiency and high-specificity gene expression in brainECs through intracranial injection at various developmental stages and through intravenous administration at all postnatal stages in mice.

Results & conclusions: Furthermore, we used rAAV-miniBEND to model sporadic cerebral cavernous malformations mediated by MAP3K3<sup>I441M</sup> and AVMs mediated by Braf<sup>V600E</sup>. Somatic expression of Braf<sup>V600E</sup> in brainECs induced an AVM phenotype, revealing that brainEC proliferation is important for AVM development. Thus, our rAAV-miniBEND system provides a widely applicable tool for cerebrovascular disease modelling and local or global brainEC gene delivery.

Abstract © the authors / Nature Biomedical Engineering (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41551-025-01538-x · PubMed 41162685.

Why it matters for pharma & biotech

  • Directly relevant to teams in gene therapy — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: gene therapy

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Nature Biomedical Engineering study find?

Thus, our rAAV-miniBEND system provides a widely applicable tool for cerebrovascular disease modelling and local or global brainEC gene delivery.

What type of study is this?

It is a preclinical (animal / model) study, published in Nature Biomedical Engineering in 2026. Here we develop a recombinant adeno-associated virus (rAAV) tool termed miniBEND (rAAV-based mini-system for brain endothelial cells, rAAV-miniBEND), which combines a minimal promoter and an optimized cis-acting element isolated from the mouse gene Tek.

Where can I read the original paper?

The original is at the publisher via DOI 10.1038/s41551-025-01538-x. PubMed ID: 41162685. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Li JL, Bi Z, Chen XJ et al.. A targeted vector for brain endothelial cell gene delivery and cerebrovascular malformation modelling.. Nature Biomedical Engineering (2026). DOI: 10.1038/s41551-025-01538-x.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/a-targeted-vector-for-brain-endothelial-cell-gene-delivery-and-cerebrova-01538x/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides